tiprankstipranks
Matinas BioPharma Holdings (MTNB)
:MTNB
US Market

Matinas BioPharma (MTNB) Stock Forecast & Price Target

Compare
1,523 Followers
See the Price Targets and Ratings of:

MTNB Financial Forecast

MTNB Earnings Forecast

Next quarter’s earnings estimate for MTNB is -$0.78 with a range of -$0.78 to -$0.78. The previous quarter’s EPS was -$0.85. MTNB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year MTNB has Outperformed its overall industry.
Next quarter’s earnings estimate for MTNB is -$0.78 with a range of -$0.78 to -$0.78. The previous quarter’s EPS was -$0.85. MTNB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.06% of the time in the same period. In the last calendar year MTNB has Outperformed its overall industry.

MTNB Sales Forecast

Next quarter’s sales forecast for MTNB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MTNB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.66% of the time in the same period. In the last calendar year MTNB has Preformed in-line its overall industry.
Next quarter’s sales forecast for MTNB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MTNB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.66% of the time in the same period. In the last calendar year MTNB has Preformed in-line its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Alliance Global Partners
Hold
Downgraded
11/01/24
Matinas BioPharma downgraded to Neutral from Buy at Alliance Global PartnersMatinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners
Maxim Group
Hold
Downgraded
10/31/24
Matinas BioPharma downgraded to Hold from Buy at MaximMatinas BioPharma downgraded to Hold from Buy at Maxim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Matinas BioPharma

Currently, no data available
Please return soon. This page is being updated.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MTNB Analyst Recommendation Trends

Rating
May 24
Jun 24
Aug 24
Oct 24
Nov 24
Strong Buy
3
3
3
2
1
Buy
2
1
0
0
0
Hold
0
0
0
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
4
3
3
3
In the current month, MTNB has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MTNB average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

MTNB Stock Forecast FAQ

What is MTNB’s average 12-month price target, according to analysts?
Currently, no data Available
What is MTNB’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MTNB, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is MTNB a Buy, Sell or Hold?
      Matinas BioPharma Holdings has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
        What is Matinas BioPharma Holdings’s price target?
        Currently, no data Available
        What do analysts say about Matinas BioPharma Holdings?
        Matinas BioPharma Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
          How can I buy shares of MTNB?
          Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis